ZYUS closes second tranche of secured loan at C$265K, total now C$445K
What's the deal? ZYUS Life Sciences Corporation, a clinical-stage company developing non-opioid pain management drugs, has closed a second tranche of secured loan financing worth C$265,000. The total raised under the secured loan now stands at C$445,000, with the company targeting up to C$2M in aggregate.
The Saskatoon-based company's subsidiary, ZYUS Life Sciences Inc., closed the second tranche on May 27, 2026, with lenders that include company insiders. One board member contributed C$45,000 to this round.
The loan carries a 12% annual interest rate, payable at maturity on November 19, 2026, and can be repaid early without penalty. It will be secured by a general security agreement, pending approval from the TSX Venture Exchange. Proceeds will go toward general working capital.
Why now? ZYUS is burning through cash while navigating complex accounting issues that have delayed its annual audited financial statements for the year ended December 31, 2025. The company disclosed that its first-quarter 2026 filings will also be late, expected to land at or shortly after the overdue annual filings are completed.
The company said it is working with external auditors on "certain complex accounting matters, including the valuation of certain assets."
What could go wrong? A clinical-stage company raising sub-million-dollar tranches of high-interest debt from its own board members is rarely a sign of strength. The 12% rate reflects meaningful risk, and the total C$2M target — even if fully raised — is modest for a life sciences firm with active drug development programmes.
Delayed financial filings add another layer of uncertainty. Unresolved asset valuation questions could signal deeper issues on the balance sheet, and prolonged delays risk regulatory scrutiny from the Exchange.
The signal: Small-cap life sciences companies without revenue continue to face a brutal funding environment. When a company turns to insider-backed secured debt at double-digit rates for working capital, it suggests the equity markets and traditional lenders aren't biting. ZYUS's situation illustrates the liquidity squeeze facing pre-commercial biotech firms — especially those that can't get their books signed off on time.
Read more: Stockwatch
